The KLHL22 antibody is a research tool designed to detect and study the Kelch-like protein 22 (KLHL22), a member of the Kelch-like (KLHL) family characterized by conserved BTB (Broad-Complex, Tramtrack, and Bric-à-brac) and Kelch repeat domains. KLHL22 functions as a substrate-specific adaptor for Cullin 3 (CUL3)-based E3 ubiquitin ligase complexes, facilitating the ubiquitination and degradation of target proteins. It plays roles in diverse cellular processes, including cell cycle regulation, DNA damage response, and metabolic homeostasis. Notably, KLHL22 has been implicated in cancer biology, where it regulates the degradation of proteins like Aurora B kinase and DCAF7. influencing tumor growth and metastasis. Dysregulation of KLHL22 is associated with malignancies such as breast cancer and hepatocellular carcinoma.
KLHL22 antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunoprecipitation to investigate its expression patterns, interaction partners, and molecular mechanisms. These antibodies are critical for validating KLHL22 knockout models and exploring its role in disease pathways. Recent studies highlight its potential as a therapeutic target, particularly in cancers with aberrant ubiquitination pathways. Validation of antibody specificity often involves knockdown/knockout controls or mass spectrometry to confirm binding accuracy. Research on KLHL22 continues to expand, driven by its emerging significance in cellular quality control and disease pathogenesis.